SLC6A1 and focal epilepsy: In conclusion, E2730 is a novel, selective, uncompetitive GAT1 inhibitor, and may be a potential ASM candidate with a wide margin between anti‐seizure effect and AEs (i.e., motor incoordination) against multiple types of epilepsy, including focal epilepsy, pharmaco‐resistant epilepsy, and orphan epilepsy syndromes.